FDA Approves Genentech’s Rituxan (rituximab) For Pemphigus Vulgaris
Genentech announced that the U.S. Food and Drug Administration (FDA) has approved Rituxan (rituximab) for the treatment of adults with moderate to severe pemphigus vulgaris (PV), a…
Read More...
Read More...
